Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Seer, Inc.NASDAQ: SEER

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$482.81M, compared with -$412.32M a year earlier.

Context

  • Retained earnings amounted to 177.4% of total assets at the end of Q1 FY2026, up 58.7 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -17.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$482.81M-3.6% QoQ
Last fiscal yearDec 2025
-$465.97M-18.8% YoY
Year agoMar 2025
-$412.32M-17.1% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.1%——
1 year-18.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(465.97M) USD
Year-over-year change
-18.8%

Retained Earnings vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -17.1% is the 9th highest of 19, against a peer median of -17.5%.
  • Retained earnings amounts to 177.4% of total assets for SEER, versus a peer median of 242.6%.
SEER Competitors
Retained Earnings for SEER and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANTXAN2 Therapeutics, Inc.Mar 2026-$250.98M USD-16.0%—286.9%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
PEPGPepGen Inc.Mar 2026-$378.88M USD-25.6%—242.4%
MNOVMediciNova, Inc.Mar 2026-$441.34M USD-2.7%—1033.5%
STTKShattuck Labs, Inc.Mar 2026-$445.3M USD-12.6%—436.0%
SEERSeer, Inc.Mar 2026-$482.81M USD-17.1%—177.4%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026-$521.72M USD-33.2%—70.8%
NRIXNurix Therapeutics, Inc.Aug 2026-$630.13M USD+31.9%—52.7%
CGEMCullinan Therapeutics, Inc.Mar 2026-$637.78M USD-53.0%—158.3%
FHTXFoghorn Therapeutics Inc.Mar 2026-$652.34M USD-13.1%—293.6%
NKTXNkarta, Inc.Mar 2026-$676.14M USD-17.3%—181.7%
PHVSPharvaris N.V.Sep 2026-€716.58M EUR-34.6%—242.9%
QSIQuantum-Si incorporatedMar 2026-$719.65M USD-16.9%—337.3%
ORICORIC Pharmaceuticals, Inc.Mar 2026-$728.01M USD-22.8%—166.7%
MLYSMineralys Therapeutics, Inc.Jun 2026-$737.58M USD-90.1%—110.4%
CCCCC4 Therapeutics, Inc.Mar 2026-$763.82M USD-15.7%—232.3%
KYMRKymera Therapeutics, Inc.Jun 2026-$1.2B USD-33.4%—72.7%
LYELLyell Immunopharma, Inc.Mar 2026-$1.64B USD-17.6%—468.8%
SANASana Biotechnology, Inc.Mar 2026-$1.9B USD-14.6%—507.6%
Peer median (excluding SEER) —-17.5%—242.6%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.81M53.21M32.5M40.75M47.29M
Short-term Investments167.26M368.03M283.73M195.66M138.61M
Net Receivables4.14M7.02M6.72M6.23M5.95M
Inventory4.15M4.63M4.49M7.44M7.8M
Other Current Assets02.1M3.08M3.25M1.89M
Total Current Assets411.7M434.98M330.51M253.32M201.53M
Property, Plant & Equipment (Net)33.23M46.41M47.37M41.37M35.24M
Goodwill00000
Intangible Assets00000
Long-term Investments93.19M5.16M56.86M63.1M54.69M
Tax Assets00000
Other Non-current Assets1.03M1.38M1.53M8.81M4.62M
Total Non-current Assets127.44M52.95M105.76M113.27M94.55M
Total Assets539.14M487.93M436.27M366.6M296.08M
Account Payables3.79M2.1M1.37M4.62M5.61M
Short-term Debt002.3M2.31M0
Tax Payables457K335K501K471K0
Deferred Revenue376K133K206K408K341K
Other Current Liabilities4.73M6.35M2.73M1.54M5.63M
Total Current Liabilities13.42M12.58M13.22M15.33M15.69M
Long-term Debt000021.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities341K320K179K48K8K
Total Non-current Liabilities22.8M28.35M26.14M23.7M21.09M
Total Liabilities36.22M40.94M39.37M39.03M36.78M
Common Stock1K1K1K1K1K
Retained Earnings(126.53M)(219.5M)(305.77M)(392.37M)(465.97M)
Accumulated OCI(536K)(1.25M)(192K)136K459K
Other Stockholders Equity00000
Minority Interest00000
Total Equity502.92M446.99M396.9M327.57M259.31M
Total Debt23.32M29.87M28.26M25.96M23.65M
Net Debt(209.49M)(23.33M)(4.24M)(14.79M)(23.63M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.